Immutep (NASDAQ:IMMP) Share Price Crosses Below 50 Day Moving Average – Here’s Why

Immutep Limited (NASDAQ:IMMP) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.18 and traded as low as $1.80. Immutep shares last traded at $1.84, with a volume of 70,057 shares trading hands.

Immutep Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 18.25 and a quick ratio of 18.25. The company’s fifty day moving average is $2.15 and its 200-day moving average is $2.35.

Institutional Trading of Immutep

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Oracle Investment Management Inc. lifted its holdings in shares of Immutep by 9.4% in the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock worth $1,316,000 after buying an additional 48,449 shares in the last quarter. XY Capital Ltd boosted its holdings in shares of Immutep by 108.3% in the 3rd quarter. XY Capital Ltd now owns 108,349 shares of the biotechnology company’s stock worth $239,000 after purchasing an additional 56,344 shares during the period. Virtu Financial LLC increased its position in Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 32,864 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Immutep by 15.4% in the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 4,700 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Immutep during the second quarter valued at approximately $26,000. Hedge funds and other institutional investors own 2.32% of the company’s stock.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.